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Abstract
G-protein-coupled receptors (GPCRs) are the largest family of
integral membrane receptors with key roles in regulating signal-
ing pathways targeted by therapeutics, but are difficult to study
using existing proteomics technologies due to their complex
biochemical features. To obtain a global view of GPCR-mediated
signaling and to identify novel components of their pathways,
we used a modified membrane yeast two-hybrid (MYTH)
approach and identified interacting partners for 48 selected full-
length human ligand-unoccupied GPCRs in their native
membrane environment. The resulting GPCR interactome
connects 686 proteins by 987 unique interactions, including 299
membrane proteins involved in a diverse range of cellular func-
tions. To demonstrate the biological relevance of the GPCR inter-
actome, we validated novel interactions of the GPR37, serotonin
5-HT4d, and adenosine ADORA2A receptors. Our data represent
the first large-scale interactome mapping for human GPCRs and
provide a valuable resource for the analysis of signaling path-
ways involving this druggable family of integral membrane
proteins.
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Introduction
G-protein-coupled receptors (GPCRs) are seven-transmembrane
proteins involved in many signal transduction pathways and in
numerous human diseases such as schizophrenia (Moreno et al,
2009), Parkinson’s disease (Pinna et al, 2005; Dusonchet et al,
2009; Gandı´a et al, 2013), hypertension (Brinks & Eckhart, 2010),
obesity (Insel et al, 2007), and multiple cancers (Lappano &
Maggiolini, 2011). GPCRs propagate ligand-specific intracellular
signaling cascades in response to extracellular stimuli—following
ligand activation, GPCRs catalyze the exchange of GDP for GTP on
the Ga subunit, leading to a decreased affinity of Ga for Gbc. The
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resulting dissociation of the hetero-trimer allows the GTP-bound Ga
and free Gbc to interact with several downstream effectors, includ-
ing adenylyl cyclases, phosphodiesterases, phospholipases, tyrosine
kinases, and ion channels (Dupre´ et al, 2009; Ritter & Hall, 2009).
Due to their involvement in signal transmission, GPCRs are
highly druggable targets for numerous pharmaceutical compounds
used for various clinical indications (Lagerstro¨m & Schio¨th, 2008).
To design successful treatments for these diseases, it is essential to
increase the depth and breadth of our understanding of the molecu-
lar events occurring during GPCR-mediated signal transduction, and
to identify all of the proteins interacting with a particular GPCR
relevant for human health.
Over the last decade, numerous biochemical, cell biological, and
genetic assays have been used to identify and characterize GPCR-
interacting partners (Daulat et al, 2009; Maurice et al, 2011). These
studies showed that, in addition to G-proteins, GPCRs also interact
with a wide variety of integral membrane proteins (e.g. other
GPCRs, ion channels, transporters, and other family receptors) and
cytosolic proteins (e.g. arrestins, GPCR kinases, Src homology 2 and
3 (SH2 and SH3), and PDZ-domain containing proteins; Ritter &
Hall, 2009; Marin et al, 2012; Hall & Lefkowitz, 2014). Despite wide
usage of biochemical assays such as co-immunoprecipitation (co-
IP), pull-down- and affinity purification-linked to mass spectrometry
(AP-MS), and protein microarrays to identify GPCR-associated
proteins (Daulat et al, 2007, 2011; Maurice et al, 2008; Chung et al,
2013; Benleulmi-Chaachoua et al, 2016), these methods have not
been widely applied to assay GPCR-related protein–protein interac-
tions (PPIs) in a systematic manner on a large scale. Furthermore,
these methods are technically difficult and time-consuming, involv-
ing harsh treatments for cell disruption and membrane protein solu-
bilization, and often require optimization for each target protein
complex examined (Chung et al, 2013; Snider et al, 2015).
Technical progress has also been made in developing methods
based on fluorescence or bioluminescence resonance energy transfer
(FRET or BRET) to study GPCR-interacting partners in live mamma-
lian cells with kinetics that are close to real-time (Lohse et al, 2012;
Ayoub & Pin, 2013). Nonetheless, the analysis of GPCR interactors
using BRET and FRET is not readily scalable to high-throughput
screening (HTS), but is rather more suited to medium-throughput
screens involving a limited number of putative hits. Aside from these
biochemical and cell biological approaches, genetic methods such as
the conventional yeast two-hybrid (YTH) system (Fields & Song,
1989) have been used to identify proteins interacting with the soluble
domains of selected GPCRs (Gavarini et al, 2004; Canela et al, 2007;
Yao et al, 2015). Unfortunately, while interesting, these studies are
restricted to the investigation of only the soluble components of
particular human GPCRs for which interacting proteins are selected
in the yeast nucleus, which is an unnatural cellular compartment for
identifying protein interactors of integral membrane proteins. Thus,
our knowledge of the interacting proteins of human GPCRs suffers
potentially serious limitations and biases due to the lack of a suitable
high-throughput technology to efficiently and comprehensively char-
acterize interacting proteins of integral membrane proteins in their
native cellular and membrane environment.
In this study, we used a modified membrane yeast two-hybrid
(MYTH) approach (Deribe et al, 2009; Snider et al, 2010; Mak et al,
2012; Usenovic et al, 2012; Huang et al, 2013; Xie et al, 2013),
specifically tailored to identify interactors of full-length integral
membrane proteins, as well as in-depth bioinformatics analysis to
create and annotate an interactome for 48 selected full-length,
clinically relevant human GPCRs in their ligand-unoccupied state,
localized to their native plasma membrane. Using this rich GPCR-
interactome resource, we then prioritized candidates by systematic
computational analysis for further biological studies, and carried
out functional studies of selected PPIs. The GPCR-interaction
network presented here will be a crucial resource for increasing our
fundamental understanding of the cellular role and regulation of this
important family of integral membrane proteins, and may facilitate
development of new disease treatments and a clearer understanding
of drug mechanisms of action.
Results
Selection of human GPCRs, generation of GPCR “baits”, and their
functional validation
We used a modified split-ubiquitin membrane yeast two-hybrid
(MYTH; Stagljar et al, 1998; Gisler et al, 2008; Deribe et al, 2009;
Snider et al, 2010) assay to define the interactomes of 48 full-length,
human, ligand-unoccupied GPCRs localized to the plasma
membrane. Specific GPCRs were selected based upon their impor-
tance for human health, specifically their direct link to human
disease. We screened 44 Class A rhodopsin-like receptors to create a
representative interactome of this most abundant family of GPCRs
in order to identify physical interaction partners, 2 Class B secretin-
like receptors (vasoactive intestinal peptide receptor 2 and retinoic
acid-induced gene 2 protein), and 2 Class F receptors (smoothened
and Frizzled7; Table EV1 lists the 48 GPCRs and related human
diseases). An overview of the complete MYTH workflow is
presented in Fig 1.
MYTH GPCR constructs (“baits”) were generated from the
selected 48 full-length human GPCR ORFs. All baits were N-termin-
ally tagged with the signal sequence of the yeast mating factor a to
encourage plasma membrane localization and stable expression in
yeast (Deribe et al, 2009), and C-terminally tagged with the C-term-
inal half of ubiquitin (Cub) fused to an artificial transcription factor
(TF) comprised of LexA and VP16 (Fig 2A; Snider et al, 2010). Bait
fusion proteins were tested for proper expression at the yeast
plasma membrane by immunofluorescence, and for lack of self-acti-
vation via the NubG/NubI test using the non-interacting yeast
plasma membrane prey protein Fur4p (Snider et al, 2010, 2013;
Fig 2B). Functionality of GPCR baits upon addition of the MYTH tag
was also demonstrated using two selected GPCR baits by measuring
changes in growth rate of bait-expressing yeast in the presence and
absence of an agonist (Fig 2C). In summary, all GPCR baits used in
this study passed stringent validation tests ensuring they are prop-
erly expressed, localized, and are functional prior to their usage in
high-throughput MYTH screens to identify protein interaction
partners.
Validation of MYTH GPCR baits using known GPCR interactions
To further confirm that the addition of the Cub-TF tag to the
C-termini of GPCR proteins does not disrupt their function and that
the MYTH system itself represents a suitable tool for use in the
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Figure 1. Workflow for generating the human full-length GPCR interactome.
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identification of GPCR-interaction partners, we used MYTH to test a
subset of 50 previously identified GPCR PPIs (Table EV2). To verify
that the absence of interaction is not a false negative due to lack of
prey protein expression, we made a side-by-side comparison of the
NubG-tagged MYTH prey construct and the prey tagged with the
original, spontaneously reconstituting wild-type NubI. Overall, 12 of
the 50 (24%) could be confirmed in the MYTH assay (Fig EV1 and
Table EV2). Note that not all previously reported interactions can be
expected to be validated by our technique, due both to differences
in the technical details of the approaches originally used (e.g. work-
ing with cell lysates instead of live cells when doing affinity purifica-
tions, working with only soluble portions of GPCRs when doing
traditional YTH) and assay conditions (e.g. our assay is carried out
in the absence of ligand). Our results therefore clearly demonstrate
the robustness and accuracy of the MYTH assay to detect GPCR-
interacting partners.
Building of the GPCR interactome
To systematically map interacting partners of human GPCRs, we
carried out MYTH screens of the 48 selected human GPCR baits
against an N-terminally NubG-tagged human cDNA library, as
described previously (Snider et al, 2010). Briefly, yeast cells
expressing MYTH baits were transformed with NubG prey pools and
plated onto SD-WLAH growth media. Positive colonies were
subjected to additional selection steps, and prey DNA was then
isolated and sequenced to identify candidate interaction partners.
The results of our extensive MYTH screens were assembled into a
A C
B
Figure 2. Expression of human MYTH GPCR “baits” in yeast cells.
A The structure of the GPCR bait proteins used in this study is shown. The signal sequence of yeast a-mating pheromone precursor (MFa) was fused to the N-
terminus of human GPCR baits, while the C-terminal fragment of ubiquitin (Cub) followed by an artificial transcription factor (TF) was fused to the C-terminus
of the baits.
B Representative sample of functional validation/localization tests performed on all GPCR baits used in this study. The top two panels show proper expression
and MYTH function of human GPCR-Cub-TF baits demonstrated using the NubG/NubI test. In this test, GPCR-Cub-TF bait and a non-interacting yeast
plasma membrane protein (Fur4p), fused to either NubI (Fur4 NubI) or NubG (Fur4 NubG) are co-expressed in yeast MYTH-reporter cells. Growth on minimal
SD medium lacking Trp and Leu (SD-WL, top panel) selects only for presence of bait and prey plasmids, while minimal SD medium lacking Trp, Leu, Ade,
and His (SD-WLAH, middle panel) selects for interaction between bait and prey. Co-expression of GPCR-Cub-TF bait with Fur4p fused to NubI leads to
activation of the reporter system and consequent growth on SD-WLAH medium, since the wild-type NubI leads to reconstitution of ubiquitin independent of
a bait–prey interaction, demonstrating that the bait protein is expressed/correctly folded. Co-expression of GPCR-Cub-TF bait and non-interacting Fur4p fused
to NubG (which does not spontaneously associate with Cub) does not lead to activation of the reporter system and growth on SD-WLAH medium,
demonstrating that the bait is not self-activating. The bottom panel shows localization of human GPCR bait proteins in THY.AP4 yeast reporter strain. Yeast
cells expressing given human GPCR baits were fixed by paraformaldehyde and digested by zymolyase. Methanol-acetone-treated yeast spheroplasts were
detected using an antibody against the transcription factor (rabbit anti-VP16) and were visualized by Cy3-conjugated secondary antibodies (shown in green).
DAPI-stained nuclei can be seen as blue fluorescence. Note that similar NubGI test and localization results were obtained for all GPCR baits used in this
study.
C Growth inhibition of the human ADRB2 and OPRM1 baits expressed in yeast THY.AP4 in response to their corresponding agonist. Growth curves were carried out in
triplicate, and curves shown are the average of three independent measurements at each individual time point. The red line shows the control yeast growth in the
absence of drug, while the black line shows growth in the presence of drug. Inhibited growth in response to drug indicates GPCR activity.
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“preliminary” interactome, which was further refined experimen-
tally using the bait dependency test, which allows us to both retest
each interaction (thereby demonstrating reproducibility) and iden-
tify/remove spuriously interacting preys which bind to unrelated
control bait (Snider et al, 2010, 2013; Lam et al, 2015). All of the
interactions that passed this secondary testing were used in subse-
quent bioinformatics analysis and filtering (to further identify and
remove false positives/spurious interactors, including signal peptide
processing and ribosomal proteins which are frequently identified
“non-specific” interactors associated with general translation and
trafficking processes). All remaining candidates were then assem-
bled into our final GPCR interactome, comprising 987 unique inter-
actions between 686 proteins, including 299 membrane proteins
(Fig 3 and Table EV3). Table EV4 lists the false positives/spurious
interactors removed from our final interactome.
To further investigate the biological context of the generated
interactome, we analyzed its enrichment for pathways, diseases,
molecular function, biological process, domains, and drug targets
(see Fig 3 and Table EV5). Using pathDIP 2.5 (Rahmati et al, 2017),
we identified significantly enriched pathways, among baits and
preys including transmembrane transport of small molecules (7.0%
of baits and preys, adjusted P = 8.7e-8), neuroactive ligand–receptor
interaction (5.0% of baits and preys, adjusted P = 2.3e-6), and
calcium regulation in the cardiac cell (7.7% of baits and preys,
adjusted P = 6.9e-6; Fig EV2A).
We investigated enrichment of diseases, functions, processes,
and domains among interacting preys (Table EV5). No diseases
were significantly enriched among preys, after adjusting P-values
for multiple testing. Diseases with the lowest unadjusted P-values
included hereditary spastic paraplegia (1.6% of preys, P = 4.5e-5),
schizophrenia (13.6% of preys, P = 1.0e-4), and neurodegenerative
disorders (6.6% of preys, P = 1.0e-4; Fig EV2B). Three functions
were significantly enriched: calcium ion transmembrane transporter
activity (2.3% of preys, adjusted P = 5.4e-3), ion channel binding
(2.2% of preys, adjusted P = 1.7e-2), and cation-transporting
ATPase activity (2.5% of preys, adjusted P = 1.9e-2). Top enriched
processes included transmembrane transport (15.5% of preys,
adjusted P = 1.1e-3), endoplasmic reticulum calcium ion homeo-
stasis (1.3% of preys, adjusted P = 1.2e-3), and ATP hydrolysis
coupled proton transport (1.3% of preys, adjusted P = 2.7e-2). No
domains were enriched after adjusting P-values for multiple testing;
top domains based on unadjusted P-values were fatty acid hydrox-
ylase (0.5% of preys, P = 8.6e-3), V-ATPase proteolipid subunit
C-like domain (0.5% of preys, P = 1.1e-2), and TRAM/LAG1/CLN8
homology domain (1.0% of preys, P = 1.2e-2). We also investi-
gated whether pairs of protein domains or conserved sites (one on
a bait and the other on a prey) were enriched among interacting
protein pairs. Top enriched pairs (adjusted P < 2.7e-12) included
bait domain GPCR, rhodopsin-like, 7TM (IPR017452) paired with
prey domains/sites Tetraspanin, conserved site (IPR018503),
Tetraspanin, EC2 domain (IPR008952), and Marvel domain
(IPR008253).
A significant number of bait GPCRs are already targeted by drugs
(28 of 48 proteins, P = 3.1e-8 relative to all proteins; Fig 3). These
drugs comprise a variety of categories, such as histamine antago-
nists, antiparkinson agents, and antipruritics agents, and affect
diverse organ systems, including nervous, cardiovascular, and respi-
ratory (Fig EV3). In total, 122 baits and preys are targeted by 737
drugs. These proteins and their interactions have substantial medi-
cal and economic significance (Fig 3). Drugs that target these
proteins include four of the top 100 prescribed drugs and five of the
top 100 selling drugs in the United States for 2014, according to data
from IMS Health, reported in Medscape (2015). These selected drugs
had over 27 million prescriptions and over $14 billion in sales.
Using the GPCR interactome, we can gain a more detailed under-
standing of how these drugs, as well as other compounds, modulate
disease-related pathways.
Orthogonal validation of MYTH-identified PPIs in
mammalian cells
As a secondary validation of our GPCR interactome, a subset of PPIs
selected from our interaction data was tested in mammalian cells
using two distinct co-immunoprecipitation (co-IP) approaches. In
the first approach, FLAG-tagged GPCR interactors were overex-
pressed in mammalian cells, pulled-down using anti-FLAG antibody,
subjected to SDS–PAGE, transferred to membranes, and probed with
commercial antibody raised against their identified endogenous
GPCR-interaction partner. We tested a subset of interactions corre-
sponding to 11 different GPCR proteins, using four MYTH-identified
interacting preys and two non-interacting negative control preys for
each. Of the 11 GPCR baits, five performed well in our analysis,
producing no more than background signal in at least one of two
negative control samples, from which we were able to confirm a
total of 13 (65%) of tested interactions (Figs 4A and EV4,
Table EV6). Proper expression of transiently transfected preys in
these blots was checked by Western blot (Fig EV5). Of the six
remaining blots, two had extremely low levels of bait expression,
while four produced signal in both negative controls comparable to
that in test samples, under multiple test conditions, preventing
meaningful interpretation of results (Fig EV4 and Table EV6). In the
second approach, an additional 14 PPIs were selected, and both
immunoprecipitation and subsequent Western development were
performed using native antibody directed against endogenously
expressed bait and prey. Of these 14 PPIs, nine (64.2%) were
successfully validated (Fig 4B and Table EV6).
As an additional orthogonal validation, we were also able to use
bioluminescence resonance energy transfer (BRET; Hamdan et al,
2006) to confirm a small subset of eight interactions, including six
not validated using either of our co-IP approaches (Table EV7).
Overall, we were able to validate a substantial number of our
tested interactions (28/40, 70%) using either co-IP and/or BRET
(Fig 4C), providing strong support for the robustness and quality of
our MYTH-generated GPCR interactome.
Functional analysis of novel, MYTH-identified GPCR PPIs
In an attempt to frame our GPCR interactome results in a biological
context, as well as demonstrate the utility of the interactome in
revealing novel interactions of biological significance, we decided to
validate several novel PPIs with potential impact in neurobiology:
specifically, the interactions of the hydroxytryptamine (serotonin)
5-HT4d (HTR4) receptor, a promising target for Alzheimer disease
(Lezoualc’h, 2007), with both GPRIN2, a G-protein-regulated
inducer of neurite outgrowth 2 that interacts with G-proteins (Chen
et al, 1999), and the Parkinson’s disease-associated receptor GPR37
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(Dusonchet et al, 2009), as well as the interaction between GPR37
and the adenosine A2A receptor (ADORA2A), also involved in
Parkinson’s disease (Pinna et al, 2005; Gandı´a et al, 2013).
To confirm the interaction of 5-HT4d with GPRIN2 and GPR37 in
a mammalian system, we carried out co-IP experiments (Fig 5A)
and BRET saturation assays (Fig 5B) in HEK-293 cells. Though the
interaction with GPRIN2 is not observed by BRET, it can be detected
by co-IP (Fig 5A, lanes 2 and 3), likely because the distance
between Rluc and YFP is greater than the BRET detection threshold
of 100 angstroms. The interaction between 5-HT4d and GPR37 was
confirmed in both assays. Co-localization of 5-HT4d with GPR37
and GPRIN2 was also observed at the plasma membrane (Fig 5C).
Additionally, Erk1/2 phosphorylation and cAMP production, in
response to stimulation of 5-HT4d, were modulated by co-expressed
GPR37 and GPRIN2, with ERK1/2 phosphorylation being largely
abolished (Fig 5D) and maximal cAMP production potentiated
(Fig 5E). This effect occurred without any modification in expres-
sion level of 5-HT4d (Fig EV6). Importantly, overexpression of
GPR37 and GPRIN2 on their own did not affect cAMP production in
response to agonist stimulation (Fig EV7).
Control experiments using overexpressed chemokine CCR5
receptor or a C-terminally truncated form of GPRIN2, which is
unable to interact with G-proteins, did not show modulation of
5-HT4d response. GPRIN2 and GPR37 were also unable to modify
the ERK and cAMP response elicited by the b2-adrenergic receptor
upon isoproterenol stimulation (Fig 5D and E). Collectively, these
Figure 3. 48 clinically relevant GPCR receptors mapped using MYTH.
GPCR interactome. Validated interactions between baits–preys and preys targeted by drugs are highlighted. Drug targets were downloaded from DrugBank, drugs sales and
prescription numbers were obtained from Medscape (2015). Bait–prey interactions are based on the IID database (black edges), MYTH detection (red edges), and validation
assays (thick red edges). Nodes are ordered and categorized by NAViGaTOR 3’s GO Molecular Function categorizer. Square nodes correspond to GPCR baits, while circular
nodes correspond to interacting prey partners.
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data demonstrate the specificity of the effect of GPRIN2 and GPR37
on 5-HT4d function.
Another GPCR interactor of GPR37 identified in our MYTH
screen was ADORA2A, an adenosine receptor highly expressed in
the striatum, a region of the brain involved in Parkinson’s disease
(Pinna et al, 2005; Gandı´a et al, 2013). The co-distribution and co-
immunoprecipitation of ADORA2A and GPR37 were confirmed in
HEK-293 cells (Fig 6A and B). Subsequently, the direct association
between ADORA2A and GPR37 was confirmed by BRET saturation
experiments (Fig 6C and D). Importantly, we did not observe a posi-
tive interaction between GPR37 and ADORA1, a related adenosine
receptor (Fig 6C). Furthermore, we explored the impact of the
ADORA2A/GPR37 interaction on the cell surface expression of these
receptors (Fig 6E). The levels of GPR37 when expressed alone are
particularly low, as previously reported (Gandı´a et al, 2013). Inter-
estingly, co-expression with ADORA2A markedly enhanced both
whole and cell surface expression of GPR37 (Fig 6E), suggesting an
ADORA2A chaperone-like function. Importantly, the expression
levels of GPR37 were not enhanced by ADORA1 co-expression
(Fig 6F), thus providing insight into the specificity of the
ADORA2A/GPR37 interaction.
Since the levels of ADORA2A appear to affect GPR37 expression,
we next aimed to explore the role of GPR37 in ADORA2A signaling
in vivo. To this end, we first validated the ADORA2A/GPR37 interac-
tion in native tissue, namely mouse striatum, by means of co-immu-
noprecipitation experiments. The immunoprecipitation of striatal
A B
C
Figure 4. Orthogonal validation of the MYTH-based GPCR interactome.
A Co-immunoprecipitations were performed using a-FLAG antibody directed against overexpressed FLAG-tagged protein corresponding to either MYTH-identified
interactor (first four lanes) or negative control (last two lanes), followed by Western blotting using antibody directed against the corresponding putative GPCR protein
interaction partner (listed below each blot). All blots shown here produced no more than background signal in at least one negative control sample, making them
suitable for use in validation of MYTH-detected interactions. (+) indicates an interaction was detected by co-IP. () indicates no interaction was detected by co-IP.
Green arrows point to the band corresponding to the indicated GPCR.
B Co-immunoprecipitations were performed using native antibody directed against the interaction partner indicated below each blot, followed by Western blotting
using native antibody directed against the other member of the interacting pair. All proteins were endogenously expressed. WCL, whole-cell lysate. Control, pull-down
using beads only.
C A total of 40 MYTH-detected interactions were successfully tested by co-immunoprecipitation or BRET and 28 were validated, a success rate of 70%. Of the 40
interactions, 34 were tested by co-immunoprecipitation approaches and 22 of these were validated, a success rate of 64.7%. BRET was used to test eight interactions,
including two tested by co-immunoprecipitation, and all were validated.
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GPR37 yielded a band of ~45 kDa corresponding to the ADORA2A
(Fig 6G). Notably, ADORA2A co-immunoprecipitation was not
observed when an unrelated antibody was used, or in striatal
membranes from GPR37/ mice, thus validating the specificity of
the interaction in native tissue. Next, we assessed the impact of
GPR37 expression on ADORA2A functionality in vivo. Dopamine
(DA) has been implicated in the central processes involved in
locomotor activity (LA) regulation and psychomotor behaviors
(Beninger, 1983). Interestingly, molecular and functional interactions
between Dopamine Receptor 2 (D2R) and ADORA2A in the nucleus
accumbens are involved in mediating LA (Ferre´ & Fuxe, 1992). Since
it appears that GPR37 interacts with both ADORA2A (from our inter-
actome) and D2R (Dunham et al, 2009), we assessed haloperidol-
induced catalepsy in GPR37 knockout mice (GPR37/) to ascertain
the role of this receptor in dopamine-/adenosine-mediated psychomo-
tor behavior. Interestingly, our results showed that in the GPR37/
mice the catalepsy scores were significantly lower (P < 0.01) than in
the GPR37+/+ mice (Fig 6H). This result suggested a possible role of
GPR37 in modulating D2R-mediated neurotransmission. Next, to test
the efficacy of ADORA2A in modulating haloperidol-induced catalepsy
we treated animals with SCH58261, a selective A2AR antagonist
(Wardas et al, 2003). The administration of SCH58261 (1 mg/kg, i.p.)
significantly (P < 0.01) reduced the catalepsy score of GPR37+/+
animals (Fig 6H), as previously reported (Wardas et al, 2003). Impor-
tantly, in the GPR37/ animals, SCH58261 completely abolished the
haloperidol-induced catalepsia (Fig 6H). These results suggest that
GPR37 might modulate D2R-mediated psychomotor behavior through
a putative ADORA2A/GPR37 oligomer in vivo.
Taken together, we were able to confirm and functionally charac-
terize two MYTH interactions, thus further demonstrating the utility
of our MYTH-based GPCR interactome as a useful resource for
disease-related biological research. Annotated interactions from this
study are made publicly available in the IID database (Kotlyar et al,
2016), with accession number #IID-003170131 (http://ophid.utoron
to.ca/iid/SearchPPIs/dataset/IID-003170131).
Discussion
Although GPCRs represent one of the most important protein classes
involved in cell signaling, comprehensive studies of their interactors
have been lacking because traditional high-throughput interactive
proteomics assays do not make use of full-length GPCRs in a natural
cellular context. In this study, we report the first systematic interac-
tome analysis of 48 clinically important human GPCRs in their
ligand-unoccupied state. We have thus created a foundational GPCR
interactome, which is necessary for assessing and understanding
complex signaling pathways and for elucidating mechanisms of drug
action. Overall, our bioinformatics analysis of the human GPCR
interactome, focusing on human diseases, provides critical and
focused research directions for GPCR signaling and function.
In establishing the utility of the MYTH system to identify human
GPCR interactions, we tested known GPCR-interacting proteins in
MYTH, confirming 24% of tested interactions. Though not all tested
interactions could be validated using MYTH, this is not unexpected
due to differences in the approaches used. For instance, many of the
interactions used in our test subset were previously identified using
affinity purification (which makes use of cell lysates instead of live
cells) or traditional YTH-based approaches (which can typically only
be performed using soluble portions of membrane proteins), while
MYTH allows for the study of full-length membrane proteins,
directly in the membrane environment of a live cell. As such, we
expect MYTH to more accurately reflect the natural cellular condi-
tions of membrane proteins, and therefore potentially better identify
membrane protein interactions, and detect fewer false positives,
than traditional methods. We were still able to recapitulate a
substantial percentage of previously identified interactions,
however, demonstrating the effectiveness of the MYTH assay for
use in the detection of GPCR interactions.
Using our MYTH screening approach, combined with compre-
hensive bioinformatics analysis, we were able to generate a richly
annotated interactome comprised of 987 unique interactions across
a total of 686 proteins. Of these, 299 were membrane proteins,
demonstrating the effectiveness of MYTH in identifying membrane
protein interactions. To further validate our interactome, we
successfully carried our orthogonal analysis using co-IP and BRET
approaches on a subset of 40 interactions spanning 10 different
GPCRs, and were able to confirm a total of 28 of 40 interactions
(70%). Failure to validate tested interactions, or identify conditions
under which certain interactions could be properly assessed by our
orthogonal methods, could be reflective of poor endogenous expres-
sion of tested GPCRs and/or aberrant interaction behavior in the
unnatural and stringent environment produced upon cellular lysis.
Overall, however, the strong confirmation rate obtained using our
orthogonal test approaches extensively supports the quality of our
MYTH GPCR interactome dataset.
◀ Figure 5. Functional interactions of GPR37 and GPRIN2 with 5-HT4d in transfected cells.A Co-immunoprecipitation in the presence and absence of 1 lM 5-HT agonist for 15 min. HEK-293 cells were transiently transfected with 5-HT4d-YFP (lanes 2, 3, 5, 6)
and myc-GPRIN2 (lanes 1–3) or GPR37 (lanes 4–6) and processed for immunoprecipitation using an anti-GFP antibody. The crude extracts (lysate) and
immunoprecipitates (IP) were analyzed by SDS-PAGE and immunoblotted using a rabbit anti-GFP or anti-Myc antibody. Data are representative of at least two
independent experiments.
B BRET donor saturation curves were performed by co-transfecting a fixed amount of 5-HT4d-Rluc and increasing amounts of 5-HT4d-YFP, GPR37-YFP, and GPRIN2-YFP
in HEK-293 cells. Data are means of three independent experiments performed in triplicate.
C Co-expression of HeLa cells transfected with 5-HT4d-YFP (green) and myc-GPR37 or myc-GPRIN2 (red) and analyzed by confocal microscopy. Superimposition of
images (merge) reveals co-distribution in orange and DAPI-stained nuclei in blue. Scale bar: 15 lm. Data are representative of at least two independent experiments.
D ERK1/2 activation in HEK-293 cells over time in response to 10 lM 5-HT agonist and the presence of overexpressed 5-HT4d and GPRIN2, GPR37, or CCR5. CCR5 is used
as a negative control. The bottom panel shows ERK1/2 activation over time, in the presence of overexpressed b2-adrenergic receptor and GPRIN2 or GPR37. Data are
means of three independent experiments performed in triplicate.
E Cyclic AMP levels in HEK-293 cells, in response to increasing concentrations of serotonin agonist and the presence of overexpressed 5-HT4d and GPRIN2, GPR37, or
CCR5. CCR5 is used as a negative control. The right panel shows cAMP levels in response to increasing isoproterenol concentrations, in the presence of overexpressed
b2-adrenergic receptor and GPRIN2 or GPR37. Data are means of three independent experiments performed in triplicate. Error bars indicate SEM.
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We also carried out additional, in-depth functional validation on
selected GPCR PPIs identified in our interactome using biochemical
and cell-based assays as well as knockout and knock-in animals.
First, we found that GPRIN2 and GPR37 physically and functionally
interact with the 5-HT4d receptor, a promising target for Alzhei-
mer’s disease. Activation of 5-HT4d has been shown to modulate
a-secretase activity, thus promoting the generation of the amyloid
precursor protein (APP)a at the expense of the Alzheimer disease-
associated APPb (Thathiah & De Strooper, 2011). This effect
involves the Gs/cAMP signaling pathway (Maillet et al, 2003).
Based on our results, the suspected beneficial effect of 5-HT4d on
Alzheimer disease development is expected to be amplified in cells
co-expressing either GPRIN2 or GPR37.
Another functionally important interactor of GPR37 was
ADORA2A, whose co-expression is observed to markedly enhance
whole and cell surface expression of GPR37, and whose interaction
with GPR37 we validated in native tissue. This interaction is particu-
larly notable in light of a reported interaction between GPR37 and
D2R (Dunham et al, 2009). Both ADORA2A and D2R are known to
co-express (Fuxe et al, 2007) and interact (Hillion et al, 2002) in
regions of the brain also expressing GPR37 (i.e. striatum), and are
involved in mediating locomotor activity (Ferre´ & Fuxe, 1992; Lein
et al, 2007). Taking our above data, together with our observations
pertaining to the effects of GPR37 deletion in mice on haloperidol-
induced catalepsy and previous findings that GPR37 affects ligand
binding affinities of D2R (Dunham et al, 2009), we hypothesize that
the interaction between GPR37 and ADORA2A (and possibly with
D2R) may play a critical role in D2R/ADORA2A-mediated psychomo-
tor behavior, and thus may function as a homeostatic regulator of
dopaminergic/adenosinergic transmission in vivo.
GPCR–GPCR heterodimerization has been widely reported
(Prinster et al, 2005), and the resultant cross-talk and mutual regu-
lation have been important for understanding the functionality of
receptors (Fuxe et al, 2014), such as ADORA2A and D2R in the brain
(Fuxe et al, 2007; Ciruela et al, 2011). Our interactome data, in
addition to functionally elucidated receptor interactions described
above, report other novel GPCR–GPCR interactions for further inves-
tigation by the scientific community, highlighting the importance of
large-scale GPCR screens, such as those performed here using
MYTH, in identifying new PPIs of potential clinical relevance.
Interestingly, interacting partners were observed to have dif-
ferent effects on GPCR function; for example, GPRIN2 and GPR37
modulate 5-HT4d signaling capacity directly, most likely through an
allosteric mechanism, whereas ADORA2A promotes GPR37 expres-
sion with important consequences on the well-established and rele-
vant ADORA2A-mediated antagonism of D2R function in vivo. These
focused analyses of novel GPCR interactions further demonstrate
the utility of our MYTH-based GPCR interactome as a powerful
resource for biological research in this area.
In summary, we report here the largest, most comprehensive
interactome study of full-length, human GPCRs carried out directly
in the context of living cells. All of the data generated in this work is
freely available for use by the scientific community [see the
Expanded View and online in the IID database (Kotlyar et al,
2016)]. Additionally, we have performed preliminary functional
validation of a selection of PPIs, which should serve as a starting
point for further work. Our GPCR-interactome data, particularly
when combined with other collaborative projects, such as the GPCR
Network (Stevens et al, 2012) and the mapping of GPCR interaction
networks performed using other recently developed technologies,
such as CHIP-MYTH (Kittanakom et al, 2014) and the mammalian
membrane two-hybrid (MaMTH; Petschnigg et al, 2014; Yao et al,
2017), will contribute significantly to our understanding of the
chemistry and biology of these clinically relevant proteins, serving
as an important tool to further our knowledge of cell signaling
processes and helping identify novel biologically important interac-
tions for use in the development and improvement of therapeutic
strategies.
◀ Figure 6. Validation of ADORA2A and GPR37 interaction in HEK-293 cells and native tissue.A Co-localization of ADORA2A and GPR37 in HEK-293 cells transiently transfected with ADORA2A-CFP, GPR37-YFP, or ADORA2A-CFP plus GPR37-YFP. Transfected cells
were analyzed by confocal microscopy. Merged images reveal co-distribution of ADORA2A-CFP and GPR37-YFP (yellow) and DAPI-stained nuclei (blue). Scale bar:
10 lm.
B Co-immunoprecipitation of ADORA2A and GPR37 from HEK-293 transiently transfected with ADORA2A (lane 1), GPR37-YFP (lane 2) or ADORA2A plus GPR37-YFP
(lane 3) using a mouse anti-GFP antibody (2 lg/ml) or a mouse anti-A2AR antibody (1 lg/ml). The crude extracts (Lysate) and immunoprecipitates (IP) were
analyzed by SDS–PAGE and immunoblotted (IB) using a rabbit anti-GPR37 (1/2,000) or rabbit anti-A2AR antibody (1/2,000).
C, D BRET saturation experiments between GPR37-Rluc and ADORA2A-YFP (black circle) or ADORA1-YFP (white circle; C), or ADORA2A-Rluc and GPR37-YFP (black circle)
or CD4R-YFP control (white circle; D) in transiently transfected HEK-293. Plotted on the x-axis is the fluorescence value obtained from the YFP, normalized with the
luminescence value of the Rluc constructs 10 min after h-coelenterazine (5 lM) incubation, and on the y-axis the corresponding BRET ratio (×1,000). mBU, mBRET
units. Data shown are from three independent experiments.
E Cell surface expression of HEK-293 cells transiently transfected with cDNA encoding ADORA2A (lane 1), GPR37-YFP (lane 2) or ADORA2A plus GPR37-YFP (lane 3). Cell
surface proteins were biotinylated and crude extracts (whole cell) and biotinylated proteins were subsequently analyzed by SDS–PAGE and immunoblotted (IB)
using a rabbit anti-GPR37 antibody (1/2,000) or a rabbit anti-A2AR antibody (1/2,000).
F Cell surface expression of HEK-293 cells transiently transfected with cDNA encoding ADORA1 (lane 1), GPR37-YFP (lane 2), or ADORA1 plus GPR37-YFP (lane 3). Cell
surface proteins were biotinylated and crude extracts (whole cell) and biotinylated proteins were subsequently analyzed by SDS-PAGE and immunoblotted (IB)
using a rabbit anti-GPR37 antibody (1/2,000) or a rabbit anti-A1R antibody (1/2,000).
G Co-immunoprecipitation of ADORA2A and GPR37 from C57BL/6J wild-type (GPR37+/+) and mutant (GPR37/) mice striatum using a rabbit anti-FLAG antibody
(4 lg/ml; lane 1) or a rabbit anti-GPR37 antibody (4 lg/ml; lane 2). The immunoprecipitates (IP) were analyzed by SDS-PAGE and immunoblotted (IB) using a
rabbit anti-GPR37 (1/2,000) or mouse anti-A2AR antibody (1/2,000).
H Involvement of GPR37 in haloperidol-induced catalepsy. The influence of systemic injection of ADORA2A antagonist SCH 58261 (1 mg/kg, i.p.) on the catalepsy
induced by haloperidol (1.5 mg/kg i.p.) was assessed in both WT (GPR37+/+) and mutant (GPR37/) mice as described in Materials and Methods. The data indicate
the mean  SEM (n = 6 per group). Asterisks denote data significantly different from the haloperidol-treated mice: **P < 0.01 and ***P < 0.001 by one-way
ANOVA with Bonferroni multiple comparison post hoc test. In the GPR37/ mice, the haloperidol plus SCH 58261 group were not significantly different (P > 0.05)
from the control (i.e. SCH 58261 alone). ¥P < 0.01 by two-way ANOVA with Bonferroni multiple comparison post hoc test for genotype and treatment comparisons.
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Materials and Methods
Full-length human bait generation
Each human GPCR was amplified by PCR and inserted by homolo-
gous recombination (Chen et al, 1992) in yeast into either of the two
bait vectors pCCW-STE or pTMBV (Dualsystems Biotech). The
primers used for the pCCW vector are 50-CCTTTAATTAAGGCCGCC
TCGGCCATCTGCAGG-30 (forward) and 50-CGACATGGTCGACGGT
ATCGATAAGCTTGATATCAGCAGTGAGTCATTTGTACTAC-30 (re-
verse). The primers used for the pTMBV4 vector are 50-CCAGTGGC
TGCAGGGCCGCCTCGGCCAAAGGCCTCCATGG-30 (forward) and 50-
ATGTCGGGGGGGATCCCTCCAGATCAACAAAGATTG-30 (reverse).
In MYTH bait vectors, the GPCRs were fused N-terminally to the
yeast mating factor alpha signal sequence to target full-length non-
yeast membrane proteins to the membrane (King et al, 1990). At the
C-terminus, the GPCR was fused in-frame with the MYTH tag
consisting of a C-terminal ubiquitin (Cub) moiety and LexA-VP16
transcription factor (TF; Fields & Song, 1989; Fashena et al, 2000).
Bait validation
The resulting MYTH bait constructs were tested as previously
described (Snider et al, 2010, 2013). Briefly, the baits were trans-
formed (Gietz & Woods, 2006) into either of the yeast reporter
strains THY.AP4 or NMY51. The correct localization of modified
baits to the membrane was confirmed by immunofluorescence using
(rabbit) anti-VP16 (Sigma Cat# V4388; 1/200); secondary (goat)
anti-(rabbit) Cy3 (Cedarlane Cat#111-165-003; 1/500)). Test MYTH
was carried out with control interacting (NubI) preys to confirm
functionality in MYTH, and with non-interacting (NubG) preys to
verify that baits do not self-activate in the absence of interacting
prey (Snider et al, 2010).
Functionality of select GPCR-Cub-TF baits (Pausch, 1997) was
confirmed (Dowell & Brown, 2009) in either wild-type THY.AP4 or
the same strain expressing a given GPCR-Cub-TF fusion. Cells were
diluted from an overnight culture to an OD600 of 0.0625 in minimum
SD or SD-Leu media, respectively. The various concentrations of
drugs, salmeterol (agonist for ADRB2) or morphine (agonist for
OPRM1), were added to a final concentration of 200 lM. The
growth rate was monitored by measuring the OD600 every 15 min
for 24 h by TECAN Sunrise plate reader.
Confirmation of known GPCR interactions by MYTH
Known GPCR-interacting partners were identified from the Inte-
grated Interactions Database (IID) (Kotlyar et al, 2016). Gateway
compatible ORFs were obtained from the Human ORFeome Collec-
tion version 8.1 (Yang et al, 2011) and used, via the Gateway
system (Life Technologies), to generate either N-terminally tagged
preys in pGPR3N (Dualsystems Biotech) or C-terminally tagged
preys in pGLigand (created in-house, Stagljar lab) depending on
which end is available for tagging. All bait prey interaction tests
were carried out using MYTH as previously described (Snider et al,
2010) in the NMY51 yeast reporter strain. Note that prior to use in
interaction tests with GPCR baits all preys were tested for promiscu-
ity by use of an artificial bait construct that consists of the single-
pass transmembrane domain of human T-cell surface glycoprotein
CD4 and the Cub-TF tag (Snider et al, 2010) and by use of the yeast
protein RGT2.
Membrane yeast two-hybrid (MYTH) screens
Bait containing yeast were transformed in duplicate with the human
fetal brain DUALmembrane cDNA library in the NubG-x orientation
(DualSystems Biotech) as previously described (Snider et al, 2010)
and plated onto synthetic dropout minus tryptophan, leucine,
adenine, and histidine (SD-Trp-Leu-Ade-His) plates with various
amounts of 3-amino-1,2,4-triazole (3-AT) as assessed by the NubG/I
control test for each individual bait. Transformants were picked and
spotted onto SD-Trp-Leu-Ade-His plates containing 3-AT and X-Gal
dissolved in N,N-dimethyl formamide. Blue colonies, expressing
putative interacting preys, were used to inoculate overnight liquid
cultures (SD-Trp) and plasmid DNA extracted. Plasmid DNA was
used to transform E. coli, DH5alpha strain for amplification. Plasmid
DNA was extracted once more and sent for sequencing as well as
used in the bait dependency test to rule out spurious interactors, as
described previously (Snider et al, 2010).
Filtering interactions
To reduce the number of false positives, we eliminated detected
interactions involving preys that carry out signal peptide processing
(GO:0006465) and ribosomal contaminants (Glatter et al, 2009). We
identified these preys using Gene Ontology (GO; Ashburner et al,
2000) annotations from the UniProt-GO Annotation database
(Matthews et al, 2009; Dimmer et al, 2012), downloaded through
the EMBL-EBI QuickGO browser (Binns et al, 2009; http://www.
ebi.ac.uk/QuickGO/GTerm?id=GO:0006465#term=annotation), on
September 10, 2016.
Identifying previously known interactions
Overlap between detected interactions and interactions already
reported in previous studies was identified using the IID database
(Kotlyar et al, 2016) ver. 2016-03 (http://ophid.utoronto.ca/iid).
Annotating interacting proteins: membrane localization
Baits and preys localized to the plasma membrane were identified
using GO annotations from the UniProt-GO Annotation database
(Dimmer et al, 2012), obtained through the EMBL-EBI QuickGO
browser (Binns et al, 2009; http://www.ebi.ac.uk/QuickGO/GTe
rm?id=GO:0006465#term=annotation) on August 31, 2016.
Process annotations and enrichment analysis
Baits and preys were annotated with GO Slim process terms from
the goslim_generic set (http://www.ebi.ac.uk/QuickGO/GMultiTe
rm#tab=choose-terms; Table EV3), downloaded on August 31,
2016.
Pathway annotations
Pathway annotations for baits and preys, as well as pathway enrich-
ment analysis, were performed using the pathDIP database
Molecular Systems Biology 13: 918 | 2017 ª 2017 The Authors
Molecular Systems Biology GPCR-interactome mapping Kate Sokolina et al
12
Published online: March 15, 2017 
(Rahmati et al, 2017) ver. 2.5 (http://ophid.utoronto.ca/pathDIP),
using the setting “Extended pathway associations” with default
parameters. P-values were FDR-corrected using the Benjamini–
Hochberg method.
Disease annotations and enrichment analysis
Disease annotations for baits and preys were downloaded from the
DisGeNET database (Pin˜ero et al, 2015) v4.0, on Aug. 31, 2016.
Disease enrichment of preys was assessed by calculating hypergeo-
metric P-values (using the human genome as the background popu-
lation), and correcting for multiple testing using the Benjamini–
Hochberg method.
Molecular function and biological process annotations and
enrichment analysis
Molecular function and biological process Gene Ontology annota-
tions were downloaded from Gene Ontology Consortium (Gene
Ontology Consortium, 2015) on November 30, 2016. Enrichment of
preys for molecular functions was calculated using the topGO
library version 2.24.0 in R version 3.3.1 (Alexa & Rahnenfuhrer,
2016). A topGOdata object was created with nodeSize = 10, and the
runTest function was used with the default algorithm (weight01)
and statistic = fisher. P-values were adjusted for multiple testing
using the Benjamini–Hochberg method. Enrichment of preys for
biological processes was calculated the same way.
Domain annotation and enrichment analysis
InterPro domain annotations were obtained from UniProt release
2016_11 (Mitchell et al, 2015; UniProt Consortium, 2015). Domain
enrichment of preys was assessed by calculating hypergeometric
P-values (using the human proteome as the background population),
and correcting for multiple testing using the Benjamini–Hochberg
method.
Domain pairs enriched among interacting bait–prey pairs were
identified in two steps. First, sets of co-occurring domains were iden-
tified for baits; each set comprised domains that always occurred
together on baits. Similarly, sets of co-occurring domains were iden-
tified on preys. Domains that did not always co-occur with others
were considered domain sets of length 1. Enrichment was subse-
quently calculated for pairs of domain sets—one set on baits and the
other on preys. Domain sets were identified for three reasons: (i) to
avoid redundant results from different domains representing the
same proteins, (ii) to avoid excessive multiple testing penalties from
non-independent tests, and (iii) for easier interpretation of results,
since a domain set clarifies that enrichment analysis cannot distin-
guish between domains within the set. After domain sets were
identified, P-values were calculated for domain set pairs using hyper-
geometric probability with the following parameters: N = the num-
ber of possible interactions involving baits (number of baits × size of
human proteome), M = the number of detected interactions, n = the
number of possible pairings between the bait domain set and the
prey domain set (number of baits with domain set × number of
human proteins with prey domain set), and m = number of interact-
ing bait–prey pairs with corresponding domain sets. Adjusted
P-values were calculated using the Benjamini–Hochberg method.
Drug target enrichment and drug category enrichment
Drug targets and drug therapeutic categories were downloaded from
DrugBank version 5 (Wishart et al, 2006). Enrichment of drug
targets among GPCR baits was calculated as a hypergeometric
P-value, using the following parameters: the number of human
protein-coding genes in the HGNC database (Gray et al, 2015)
(19,008), the number drug targets in DrugBank (4,333), the number
of baits (48), and the number of baits that are drug targets (28).
Enrichment of therapeutic categories among baits and preys was
calculated as hypergeometric P-values using the following parame-
ters: the number of human protein-coding genes in the HGNC data-
base (Gray et al, 2015) (19,008), the number of targets in a
therapeutic category, the number of baits and preys (686), and the
number of baits and preys that are targets in the category. We calcu-
lated Q-values (P-values adjusted for multiple testing) using the
Benjamini–Hochberg method.
Drugs sales and prescription numbers were obtained from
Medscape (2015).
PPI predictions
Predictions were obtained using the FpClass algorithm (Kotlyar
et al, 2015): a probabilistic method that integrates diverse PPI
evidence including compatibility of protein domains, gene co-
expression, and functional similarity, as well as other methods
integrated in IID (version 2016-03, http://ophid.utoronto.ca/iid;
Kotlyar et al, 2016). Resulting networks were visualized in NAVi-
GaTOR 3.0 (http://ophid.utoronto.ca/navigator; Brown et al, 2009).
Confirmation of interactions by co-immunoprecipitation
Approach 1—Endogenous baits and transiently transfected FLAG-
tagged preys
293T cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% FBS, 100 U penicillin, and 100 lg/ml
streptomycin (Fisher Scientific, cat# SV30010) and split at 80% con-
fluence. To co-immunoprecipitate GPCRs with their preys, plasmids
encoding FLAG-tagged preys were transiently transfected in 293T
cells and their interaction with GPCR was detected using Western
blotting with anti-GPCR antibodies.
Briefly, 293T cells were plated at 40% confluence overnight. On
the following morning, cells were transfected using calcium phos-
phate [Ca3(PO4)2] kit ProFection from Promega (cat# E1200) follow-
ing manufacturer’s instructions. 70 lg of plasmid DNA was added
to CaCl2 and water, and the mixture was added to HEPES-buffered
saline while vortexing. The mixture was incubated at room tempera-
ture for 30 min. Prior to adding to cells, the mixture was vortexed
again. After 24 h post-transfection, 2 × 150 mm dishes of 293T
cells/plasmid were harvested and the cells were washed with ice-
cold PBS. After that, cells were cross-linked with 0.5 mM DSP at
room temperature for 30 mins followed by quenching excessive DSP
with a buffer containing 0.1 M Tris–HCl, pH 7.5, and 2 mM EDTA.
Detached cells were centrifuged at 400 g for 10 min at 4°C. The cell
pellet was lysed in RIPA buffer containing 1× protease inhibitor
cocktail (Sigma Aldrich, cat# P2714) on ice for 30 min with occa-
sional agitation. To aid lysis, cells were passed through a 21G
needle 10×. Lysate was cleared by centrifugation at 16,000 g for
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15 min at 4°C. A volume of cell lysate containing 10 mg protein
was adjusted to 1 ml with RIPA containing 1× protease inhibitor
cocktail and 3 lg of each anti-GPCR receptor antibody were
added. The tube rotated for 1 h at 4°C followed by addition of
100 ll of lMACS protein-G magnetic microbeads (Miltenyi, cat#
130-071-101) with continued rotation for additional 4 h at 4°C.
lMACS columns (Miltenyi, cat# 130-092-444) were equilibrated
with RIPA 1× protease inhibitor cocktail. The microbeads
suspension was passed through the columns, and the retained
microbeads were washed 3× with 800 ll of RIPA 0.1% of deter-
gents and 1× protease inhibitor cocktail followed by another 2×
washes with 500 ll detergent-free RIPA containing 1× protease
inhibitor cocktail only. Proteins bound to the microbeads were
released by addition of 25 ll Laemmli loading buffer at 95°C 2×.
Eluates were analyzed using SDS-PAGE and visualized using
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Fisher, cat# 34094).
Approach 2—Endogenous baits and preys
Ten 150-mm dishes of HEK-293 cells were harvested and centri-
fuged at 400 g for 10 min. The cell pellet was resuspended in 15 ml
phosphate-buffered saline (PBS) and mixed with an equal volume
of cross-linking reagent (1 mM dithiobis-succinimidyl propionate
prepared in PBS). After 30-min incubation, the cross-linked
cells pelleted by centrifugation at 400 g were lysed in IPLB (im-
munoprecipitation lysis buffer containing 1% digitonin and 1×
protease inhibitor cocktail) for 30 min. The lysates were then centri-
fuged at 16,000 g for 15 min at 4°C. The cell lysate containing
~10 mg of protein was adjusted to 1 ml with IPLB (containing 1%
digitonin and 1× protease inhibitor cocktail) and 3 lg of antibody
specific to the target protein was added to the mixture. The samples
were incubated with 100 ll of lMACS protein-G magnetic beads
followed by 5-h gentle rotation at 4°C. The bead suspension was
passed through the lMACS columns (equilibrated with IPLB
containing 1% digitonin and 1× protease inhibitor), and the retained
beads were washed three times with 800 ll of IPLB (0.1% digitonin
and 1× protease inhibitor) followed by another two washes with
500 ll IPLB (1× protease inhibitor only). Co-purifying protein that
bound to the beads was eluted by the addition of 25 ll Laemmli
loading buffer at 95°C, and analyzed by SDS-PAGE and
immunoblotting using protein-specific antibody.
Antibodies used in co-immunoprecipitation experiments
Santa Cruz: OPRL1 (sc-15309), TSHR (sc-13936), OPRM1 (sc-
15310), AGTR1 (sc-1173-G), PTAFR (sc-20732), C5L2 (sc-368573),
HRH (sc-20633), CHRM5 (sc-9110), OXTR (sc-33209). Abcam:
ADRB2 (ab36956), HNRPK (ab52600), F2RL (ab124227), TTYH1
(ab57582), PRNP (ab52604), MGLL (ab24701), ATP2A2 (ab2861),
FA2H (ab54615), HSPA1B (ab79852). Cell Signaling: GABBR1
(3835). ProteinTech: GPR37 (14820-1-AP), FZD7 (16974-1-AP).
Confirmation of interactions by BRET
To confirm select interactions using BRET as an orthogonal valida-
tion assay, GPCR interactors identified in MYTH assays were fused
to GFP2, a blue-shifted variant of GFP, to act as BRET acceptor, and
GPCR receptors to RLucII, a brighter Renilla luciferase mutant, to
act as donor, then plotted as increasing BRET levels compared to
GFP/Rluc, as previously described (Mercier et al, 2002; Loening
et al, 2006; Breton et al, 2010).
5-HT4d experiments
Materials
The cDNAs encoding human GPR37 and GPRIN2 were purchased
from UMR cDNA Resource Center. The 5-HT4d-Rluc, 5-HT4d-YFP,
and HA-CCR5 constructs have been described elsewhere
(Berthouze et al, 2005; Tadagaki et al, 2012). An N-terminally
6xMyc tagged version of GPRIN2 and GPR37 and C-terminally YFP
tagged GPR37-YFP and GPRIN2-YFP fusion proteins were obtained
by PCR using the Phusion High-Fidelity DNA Polymerase (Finn-
zymes). All constructs were inserted in the pcDNA3.1 expression
vector and verified by sequencing. The C-terminally deleted
GPRIN2DCter construct was obtained by mutagenesis by introduc-
ing a stop codon resulting in a truncated protein of 149 amino
acids.
Co-immunoprecipitation
HEK-293 cells transiently transfected with 5-HT4d-YFP and myc-
GPRIN2 or GPR37 were analyzed in the presence and absence of
1 lM 5-HT for 15 min and processed for immunoprecipitation
using a monoclonal anti-GFP antibody. Crude extracts and
immunoprecipitates were analyzed by SDS–PAGE and immunoblot-
ted using rabbit anti-GFP or anti-myc antibodies.
BRET
BRET donor saturation curves were performed in HEK-293 cells by
co-transfecting a fixed amount of 5-HT4d-Rluc and increasing
amounts of 5-HT4d-YFP, GPR37-YFP, and GPRIN2-YFP as described
previously (Maurice et al, 2010).
Fluorescence microscopy
HeLa cells expressing 5-HT4d-YFP and Myc-GPR37 or Myc-GPRIN2
were fixed, permeabilized with 0.2% Triton X-100, nuclei stained
with DAPI (blue) and incubated with monoclonal anti-Myc antibody
(Sigma, St Louis, MO; 2 mg/ml) and subsequently with a Cy3-
coupled secondary antibody. GFP, Cy3, and DAPI labeling was
observed by confocal microscopy.
Signaling assays
ERK1/2 activation and cyclic AMP levels were determined in HEK-
293 cells as described previously (Guillaume et al, 2008).
ADORA2A experiments
Materials
The cDNA encoding the human GPR37 (Unigene ID: Hs.725956;
Source BioScience, Nottingham, UK) was amplified and subcloned
into the HindIII/EcoRI restriction sites of the pEYFP vector (Invitro-
gen, Carlsbad, CA, USA) using the iProof High-Fidelity DNA poly-
merase (Bio-Rad, Hercules, CA, USA) and the following primers:
FGPR37 (50-CGCAAGCTTATGCGAGCCCCGG-30) and RGPRYFP (50-
CGCGAATTCCGCAATGAGTTCCG-30). GPR37 was also subcloned in
the HindIII/KpnI restriction sites of the pRluc-N1 vector (Perkin–
Elmer, Waltham, MA, USA) using the following primers: FGPR37
and RGPRLuc (50-CGCGGTACCGCGCAATGAGTTCCG-30).
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The constructs for the human adenosine A2A receptor (namely,
ADORA2A-YFP and ADORA2A-Rluc) were obtained as previously
described (Gandia et al, 2008) and ADORA2A-CFP was obtained by
subcloning the adenosine receptor from ADORA2A-YFP into the
pECFP-N1 plasmid.
A homemade rabbit anti-GPR37 polyclonal antibody (Lopes et al,
2015) was used. Other antibodies used were rabbit anti-A2AR
(Ciruela et al, 2004), mouse anti-A2AR (05-717, Millipore, Temecula,
CA, USA), rabbit anti-FLAG (F7425, Sigma) and rabbit anti-A1R
(PA1-041A, Affinity BioReagents, Golden, CO, USA).
C57BL/6J wild-type and GPR37/ mice with a C57BL/6J genetic
background (Strain Name: B6.129P2-Gpr37tm1Dgen/J; The Jackson
Laboratory, Bar Harbor, ME, U.S.A.) were used. Mice were housed
in standard cages with ad libitum access to food and water, and
maintained under controlled standard conditions (12-h dark/light
cycle starting at 7:30 AM, 22°C temperature and 66% humidity).
The University of Barcelona Committee on Animal Use and Care
approved the protocol, and the animals were housed and tested in
compliance with the guidelines described in the Guide for the Care
and Use of Laboratory Animals (Clark et al, 1997) and following the
European Community, law 86/609/CCE.
Immunocytochemistry
HEK-293 cells were transiently transfected with ADORA2A-CFP,
GPR37-YFP, or ADORA2A-CFP plus GPR37-YFP using the Trans-
Fectin Lipid Reagent (Bio-Rad) and following the instructions
provided by the manufacturer. The cells were analyzed by confocal
microscopy 48 h after transfection. Superimposition of images
(merge) reveals co-distribution of ADORA2A-CFP and GPR37-YFP in
yellow and DAPI-stained nuclei in blue.
Co-immunoprecipitation
Membrane extracts from HEK-293 cells and C57BL/6J mouse stria-
tum were obtained as described previously (Burguen˜o et al, 2003).
Membranes were solubilized in ice-cold radioimmunoassay (RIPA)
buffer (150 mM NaCl, 1% NP-40, 50 mm Tris, 0.5% sodium deoxy-
cholate, and 0.1% SDS, pH 8.0) for 30 min on ice in the presence of
protease inhibitor (Protease Inhibitor Cocktail Set III, Millipore,
Temecula, CA, USA). The solubilized membrane extract was then
centrifuged at 13,000 ×g for 30 min, and the supernatant was incu-
bated overnight with constant rotation at 4°C with the indicated
antibody. Then, 50 ll of a suspension of Protein A–agarose (Sigma)
or TrueBlot anti-rabbit Ig IP beads (eBioscience, San Diego, CA) was
added and incubated for another 2 h. The beads were washed with
ice-cold RIPA buffer and immune complexes were dissociated,
transferred to polyvinylidene difluoride membranes and probed
with the indicated primary antibodies followed by horseradish
peroxidase (HRP)-conjugated secondary antibodies. The immunore-
active bands were detected using Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific) and visualized in a LAS-3000
(FujiFilm Life Science).
BRET
For BRET saturation experiments, HEK-293 cells transiently trans-
fected with a constant amount of cDNA encoding the Rluc
constructs and increasing amounts of YFP tagged proteins were
rapidly washed twice in PBS, detached and resuspended in Hank’s
balanced salt solution (HBSS) buffer (137 mM NaCl, 5.4 mM KCl,
0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM
MgSO4, 4.2 mM NaHCO3, pH 7.4), containing 10 mM glucose and
processed for BRET determinations using a POLARstar Optima
plate-reader (BMG Labtech, Durham, NC, USA; Ciruela et al, 2015)
or Mithras plate reader (Berthold Technologies; Cecon et al, 2015).
Cell surface expression
HEK-293 cells were transiently transfected with the cDNA encoding
ADORA2A, ADORA1, GPR37-YFP, ADORA2A plus GPR37-YFP or
ADORA1 plus GPR37-YFP. Cell surface labeling was performed by
biotinylation experiments (Burguen˜o et al, 2003). Crude extracts
and biotinylated proteins were subsequently analyzed by SDS–PAGE
and immunoblotted using a rabbit anti-GPR37 antibody (1/2,000), a
rabbit anti-A2AR antibody (1/2,000), or a rabbit anti-A1R antibody
(1/2,000). The primary bound antibody was detected as described
before.
Catalepsy score
Catalepsy behavior was induced by the D2R antagonist haloperidol
(1.5 mg/kg, i.p.), as previously described (Chen et al, 2001). Mice
used in the catalepsy test were 2-month-old males. The animals were
randomly distributed among the experimental groups. Fifteen min
before animals were administered either saline or SCH58261 (1 mg/kg,
i.p.), an A2AR antagonist. The cataleptic response was measured as
the duration of an abnormal upright posture in which the forepaws
of the mouse were placed on a horizontal wooden bar (0.6 cm of
diameter) at 4.5 cm high from the floor. The latency to move at least
one of the two forepaws was recorded 2 h after haloperidol adminis-
tration. The test was carried out by an experimenter who was blind
to the identity of treatments and the cataleptic time latency was
automatically recorded and counted by an independent researcher.
A cutoff time of 180 s was imposed. Catalepsy testing was
performed under dim (16 lux) light conditions. The sample size was
initially set as five determinations per experimental condition.
Subsequently, the statistical power was calculated using the IBM
SPSS Statistics (version 24) software. Accordingly, the sample size
was then designed to achieve a minimum of 80% statistical power.
Data availability
All interactome data are available in the IID database (accession:
IID-003170131; http://iid.ophid.utoronto.ca/SearchPPIs/dataset/IID-00
3170131).
Expanded View for this article is available online.
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